Eli Lilly and Company (LLY)vsSophia Genetics SA (SOPH)
LLY
Eli Lilly and Company
$851.21
+9.80%
HEALTHCARE · Cap: $760.43B
SOPH
Sophia Genetics SA
$5.28
+5.60%
HEALTHCARE · Cap: $358.34M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 84251% more annual revenue ($65.18B vs $77.27M). LLY leads profitability with a 31.7% profit margin vs -102.2%. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
SOPH
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
-3.2%
Fair Value
$4.63
Current Price
$5.28
$0.65 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Revenue surging 22.4% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 28.7x book value
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bull Case : SOPH
The strongest argument for SOPH centers on Revenue Growth. Revenue growth of 22.4% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : SOPH
The primary concerns for SOPH are EPS Growth, Market Cap, Debt/Equity.
Key Dynamics to Monitor
SOPH carries more volatility with a beta of 1.04 — expect wider price swings.
LLY is growing revenue faster at 42.6% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (78/100 vs 26/100), backed by strong 31.7% margins and 42.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Sophia Genetics SA
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Sophia Genetics SA (SOPH) is a trailblazer in data-driven medicine, specializing in advanced genomic and clinical data analytics aimed at improving patient outcomes. Leveraging state-of-the-art machine learning algorithms, the company offers a robust platform that empowers hospitals and laboratories to decode complex genomic information, thereby enabling personalized treatment approaches, particularly in oncology, rare diseases, and hereditary conditions. With a strong global presence and strategic alliances with leading healthcare institutions, Sophia Genetics is dedicated to revolutionizing healthcare through precision medicine, reinforcing its status as a key player in the genomics sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?